Atlas Trials

Aligos Therapeutics

15 clinical trials · Sponsor

Sort:Newest firstOldest first

◉ Watch Aligos Therapeutics

RecordFirmDate
Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function (NCT07342881)Aligos Therapeutics2026-02-20
Single-Dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Subjects With Moderate Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function (NCT07342868)Aligos Therapeutics2026-01-30
A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) (NCT06963710)Aligos Therapeutics2025-07-15
A Phase 1 Study in Healthy Volunteers to Evaluate the Relative Bioavailability of ALG-055009 Formulations (NCT06959888)Aligos Therapeutics2025-03-25
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Renal Impairment and in Healthy Subjects With Normal Renal Function (NCT06698549)Aligos Therapeutics2025-02-20
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function (NCT06568861)Aligos Therapeutics2025-01-13
A Multi-part Study of ALG-000184 to Evaluate Safety, Tolerability, Pharmacokinetics and Drug-drug Interaction Potential After Single and Multiple Doses in Healthy Volunteers (NCT06672900)Aligos Therapeutics2025-01-09
ALG-055009 in Non-cirrhotic Adults With MASH (HERALD) (NCT06342947)Aligos Therapeutics2024-04-01
A Phase 1 Study to Evaluate the Drug-Drug Interaction Potential Between ALG-055009 and Statin Therapy(Ies) (NCT06191991)Aligos Therapeutics2023-11-03
A First-in-Human Multi-Part Phase 1 Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics, and Drug-Drug Interaction Potential of Single and Multiple Doses of ALG-097558 (NCT05840952)Aligos Therapeutics2023-07-04
A Study of ALG-125755 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics After Single Doses in Healthy Volunteers, and Single and Multiple Doses in CHB Subjects (NCT05561530)Aligos Therapeutics2022-10-07
A Study of ALG-055009 in Healthy Volunteers and Subjects With Hyperlipidemia (NCT05090111)Aligos Therapeutics2021-12-01
A Study of ALG-020572 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single Doses in Healthy Volunteers and Multiple Doses in CHB Subjects (NCT05001022)Aligos Therapeutics2021-09-25
A Study of ALG-000184 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects (NCT04536337)Aligos Therapeutics2020-10-22
A Study of ALG-010133 Drug to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics After Single and Multiple Doses in Healthy Volunteers and CHB Subjects (NCT04485663)Aligos Therapeutics2020-08-17

Track Aligos Therapeutics automatically

Every clearance here is in the API, with alerts when new ones post.